SCHEDULE 13G/A: Redmile Group Discloses 4.6% Stake in Amicus Therapeutics, Including Warrants
Beneficial Ownership Report
Redmile Group, LLC and its principal Jeremy C. Green have disclosed a beneficial ownership of 4.6% in Amicus Therapeutics, Inc., comprising common stock and shares issuable from warrants.
Summary
- Redmile Group, LLC and its principal, Jeremy C. Green, have filed an Amendment No. 13 to Schedule 13G, disclosing their beneficial ownership in Amicus Therapeutics, Inc.
- As of December 31, 2024, Redmile Group, LLC and Jeremy C. Green beneficially own an aggregate of 14,184,495 shares of Amicus Therapeutics, Inc. Common Stock.
- This ownership represents 4.6% of the total outstanding Common Stock, calculated based on 298,805,773 shares outstanding as of October 25, 2024, plus 7,129,605 shares issuable from warrants.
- The beneficial ownership is comprised of 7,054,890 shares of Common Stock and 7,129,605 shares of Common Stock issuable upon exercise of certain warrants.
- Both Redmile Group, LLC and Jeremy C. Green hold shared voting power and shared dispositive power over all 14,184,495 shares.
- The securities are held by private investment vehicles managed by Redmile Group, LLC, and the beneficial ownership is disclaimed except to the extent of pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
This document does not contain forward-looking statements or guidance regarding the issuer's future performance or outlook.
Industry Context
This filing is a standard disclosure of significant ownership by an investment firm in a publicly traded biotechnology company, reflecting an investment position rather than operational or strategic industry trends.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2024-10-25 | Date as of which 298,805,773 shares of Common Stock were reported outstanding by Amicus Therapeutics in its Form 10-Q. |
| 2024-11-06 | Date Amicus Therapeutics filed its Form 10-Q for the quarterly period ended September 30, 2024. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-02-14 | Date the Schedule 13G statement was signed and filed. |
Keywords
Amicus Therapeutics, Redmile Group, Jeremy C. Green, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Investment Management, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.